Phase 3 Study of Recombinant von Willebrand Factor in Patients With Severe von Willebrand Disease

Recombinant von Willebrand factor (rVWF) demonstrates efficacy for on-demand treatment of bleeding in severe von Willebrand disease (VWD). The study evaluates the hemostatic efficacy/safety profile of rVWF, with/without recombinant factor VIII (rFVIII), in patients with severe VWD undergoing surgery. The collected data supports the efficacy and safety profile of rVWF in patients with severe VWD undergoing elective surgery. To read further more about the study and the results of it check here.